Monoclonal anti-interleukin 2 (15-2) antibody binding to granular layer keratinocytes of human skin

J Invest Dermatol. 1986 Apr;86(4):359-62. doi: 10.1111/1523-1747.ep12285581.

Abstract

Among several monoclonal antibodies (moABs) directed against human interleukin 2 (IL-2), the 15-2 moAB raised in our laboratory against unglycosylated recombinant IL-2 (produced in Escherichia coli) cross-reacted with a human skin epitope. This moAB gave a strong staining on the cell-surface membranes of keratinocytes from the granular layer of the epidermis. In addition, the 15-2 moAB stained 15% of epidermal cell suspensions obtained from suction blisters and reacted with cells from the spinous layer in parakeratosis and psoriasis, as well as with spinous epithelioma cells. Preincubation of the 15-2 moAB with pure human recombinant IL-2 abrogated skin binding, whereas a polyclonal antikeratin antiserum did not block 15-2 skin binding. Two other anti-IL-2 moABs, one directed against unglycosylated recombinant IL-2 (17-2 moAB) and one against glycosylated natural IL-2 (9B11 IE5 moAB), were unreactive on skin. Taken together, the data suggest that the 15-2 moAB binds to an epitope cross-reacting with, but different from, IL-2 which is located in the cell-surface membranes of granular layer cells. This cross-reactive epitope may provide a useful probe for the study of human epidermal cell differentiation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal*
  • Binding Sites, Antibody*
  • Epidermis / metabolism*
  • Epidermis / pathology
  • Humans
  • Interleukin-2 / immunology*
  • Interleukin-2 / metabolism
  • Keratins
  • Mice
  • Mice, Inbred BALB C
  • Parakeratosis / metabolism
  • Parakeratosis / pathology
  • Psoriasis / metabolism
  • Psoriasis / pathology
  • Staining and Labeling

Substances

  • Antibodies, Monoclonal
  • Interleukin-2
  • Keratins